Literature DB >> 23538190

Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire scores in patients with colorectal cancer.

Carlos King Ho Wong1, Cindy L K Lam, Y F Wan, Donna Rowen.   

Abstract

OBJECTIVES: To develop a mapping model for estimating six-dimensional health state short form (SF-6D) utility scores from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (QLQ-C30 and QLQ-CR29) scores in patients with colorectal cancer (CRC), with and without adjustment for clinical and demographic characteristics.
METHODS: Ordinary least squares regression models were applied to a cross-sectional data set of 216 patients with CRC collected from a regional hospital in Hong Kong. Item responses or scale scores of cancer-specific (QLQ-C30) and colorectal-specific health-related quality-of-life (QLQ-CR38/CR29) data and selected demographic and clinical characteristics of patients were used to predict the SF-6D scores. Model goodness of fit was examined by using exploratory power (R(2) and adjusted R(2)), Akaike information criterion, and Bayesian information criterion, and predictive performance was evaluated by using root mean square error, mean absolute error, and Spearman's correlation coefficients between predicted and observed SF-6D scores. Models were validated by using an independent data set of 56 patients with CRC.
RESULTS: Both scale and item response models explained more than 67% of the variation in SF-6D scores. The best-performing model based on goodness of fit (R(2) = 75.02%), predictive ability in the estimation (root mean square error = 0.080, mean absolute error = 0.065), and validation data set prediction (root mean square error = 0.103, mean absolute error = 0.081) included variables of main and interaction effects of the QLQ-C30 supplemented by QLQ-CR29 subset scale responses and a demographic (sex) variable.
CONCLUSIONS: SF-6D scores can be predicted from QLQ-C30 and QLQ-CR38/CR29 scores with satisfactory precision in patients with CRC. The mapping model can be applied to QLQ-C30 and QLQ-CR38/CR29 data sets to produce utility scores for the appraisal of clinical interventions targeting patients with CRC using economic evaluation.
Copyright © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23538190     DOI: 10.1016/j.jval.2012.12.004

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  9 in total

1.  The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.

Authors:  Nick Kontodimopoulos
Journal:  Qual Life Res       Date:  2014-11-13       Impact factor: 4.147

2.  Improving the mapping of condition-specific health-related quality of life onto SF-6D score.

Authors:  Yingsi Yang; M Y Wong; Cindy L K Lam; Carlos K H Wong
Journal:  Qual Life Res       Date:  2014-03-29       Impact factor: 4.147

3.  Mapping the cancer-specific FACT-B onto the generic SF-6Dv2.

Authors:  Azin Nahvijou; Hossein Safari; Mahmood Yousefi; Marziyeh Rajabi; Morteza Arab-Zozani; Hosein Ameri
Journal:  Breast Cancer       Date:  2020-07-25       Impact factor: 4.239

4.  Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.

Authors:  Admassu N Lamu; Jan Abel Olsen
Journal:  Qual Life Res       Date:  2018-09-01       Impact factor: 4.147

5.  Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.

Authors:  Hosein Ameri; Mahmood Yousefi; Mehdi Yaseri; Azin Nahvijou; Mohammad Arab; Ali Akbari Sari
Journal:  J Gastrointest Cancer       Date:  2020-03

6.  Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness.

Authors:  Melanie Lindenberg; Astrid Kramer; Esther Kok; Valesca Retèl; Geerard Beets; Theo Ruers; Wim van Harten
Journal:  BMC Cancer       Date:  2022-05-06       Impact factor: 4.638

7.  Clinical correlates of health preference and generic health-related quality of life in patients with colorectal neoplasms.

Authors:  Carlos K H Wong; Cindy L K Lam; Jensen T C Poon; Dora L W Kwong
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

8.  Health-related quality of life and risk of colorectal cancer recurrence and All-cause death among advanced stages of colorectal cancer 1-year after diagnosis.

Authors:  Carlos K H Wong; Wai-Lun Law; Yuk-Fai Wan; Jensen Tung-Chung Poon; Cindy Lo-Kuen Lam
Journal:  BMC Cancer       Date:  2014-05-17       Impact factor: 4.430

Review 9.  Systematic review of health state utility values for economic evaluation of colorectal cancer.

Authors:  Kim Jeong; John Cairns
Journal:  Health Econ Rev       Date:  2016-08-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.